A regimen including oral paclitaxel plus Athenex (encequidar) in combination with a PD-1 inhibitor and carboplatin showed positive results in triple-negative, high-risk, early-stage breast cancer. The oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.
